Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival-Reference-Cited by-同舟云学术

Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival

Published:2020-01-29 Issue:6 Volume:61 Page:1512-1515
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lad Deepesh P.¹^ORCID,Tejaswi V.¹,Jindal Nishant¹,Malhotra Pankaj¹,Khadwal Alka¹,Prakash Gaurav¹,Jain Arihant¹,Sreedharanunni Sreejesh²,Sachdeva Manupdesh Singh²,Naseem Shano²,Varma Neelam²,Varma Subhash¹

Affiliation:

1. Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India;

2. Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1719099

Reference14 articles.

1. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

2. The CLL-IPI applied in a population-based cohort

3. Real‐world clinical experience in the Connect ® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres

4. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry

5. PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Do We Manage Chronic Lymphocytic Leukemia in India;Current Hematologic Malignancy Reports;2024-02-01

2. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia;Frontiers in Oncology;2021-08-02

3. The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report;BMC Women's Health;2021-05-01

4. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients;Leukemia;2021-02-04

5. Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients;Indian Journal of Hematology and Blood Transfusion;2020-11-13